For more on this story:
Novo Nordisk’s blockbuster obesity drug Wegovy has scored FDA approval for reducing the risk of heart conditions like heart attack and stroke. In a cardiovascular outcomes trial, Wegovy was shown to cut the risk of major adverse cardiovascular events by 20 percent compared to placebo. Sales of the blockbuster drug totalled $4.6 billion in 2023.
#Wegovy #WeightLossDrug #ObesityDrug #NovoNordisk #Semaglutide #GLP1Agonist #HeartHealth #CardiovascularDisease #FDA #FDAApproval #WeightLoss #Obesity #goli gummies for weight loss #cost of golo diet pills #life style keto gummies #fat burn keto pills #keto crave acv gummies 525 mg
Weight Loss Blockbuster Wegovy Wins Expanded Approval for Heart Benefits [_5C9kTHiORA]
For more on this story:
Novo Nordisk’s blockbuster obesity drug Wegovy has scored FDA approval for reducing the risk of heart conditions like heart attack and stroke. In a cardiovascular outcomes trial, Wegovy was shown to cut the risk of major adverse cardiovascular events by 20 percent compared to placebo. Sales of the blockbuster drug totalled $4.6 billion in 2023.
#Wegovy #WeightLossDrug #ObesityDrug #NovoNordisk #Semaglutide #GLP1Agonist #HeartHealth #CardiovascularDisease #FDA #FDAApproval #WeightLoss #Obesity #goli gummies for weight loss #cost of golo diet pills #life style keto gummies #fat burn keto pills #keto crave acv gummies 525 mg